Navigation Links
Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable,Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical,Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkin's Lymphoma

eb site at www.accentia.net.

Forward-Looking Statements

Statements in this release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, statements about Revimmune(TM) SinuNase(TM), BiovaxID(TM), AutovaxID(TM), CRSFungal Profile(TM) and any other statements relating to products, product candidates, product development programs the FDA or clinical study process including the commencement, process or completion of clinical trials or the regulatory process. Such statements may include, without limitation, statements with respect to the Company's plans, objectives, expectations and intentions and other statements identified by words such as "may," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause the actual results of Accentia to be materially different from historical results or from any results expressed or implied by such forward-looking statements. These factors include, but are not limited to, risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval for product candidates; competition from other pharmaceutical or biotechnology companies; and the additional risks discussed in filings with the Securities and Exchange Commission. All forward-looking statements are qualified in their entirety by this cautionary statement, and Accentia undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof.

Contact

Biovest International, Inc., New York, NY
Steven Arikian, MD
Chairman and Chief Executive Officer
212-686-4100 ext 8640





Page: 1 2 3 4 5

Related medicine technology :

1. Pieris Progresses Proprietary Asthma Program: Validation of Pulmonary Delivery of Anticalin-Based Protein Product Candidate
2. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
3. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
4. Velcade (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma
5. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
6. Research Documents Scalable Production, Survival Following Engraftment and Positive Impact on Cardiac Function in Infarcted Rats for Gerons Human Embryonic Stem Cell-Based Therapeutic for Heart Failure
7. Research Indicates Gerons Human Embryonic Stem Cell-Based Therapeutic for Spinal Cord Injury Evades Direct Attack by the Human Immune System
8. Celator Pharmaceuticals Study Shows Anti-Tumor Activity in Cancer Patients Treated with Therapy Based on Ratiometric Dosing
9. Eloxatin (oxaliplatin injection)-Based Chemotherapy Sets New Treatment Benchmark in Patients With Metastatic Colorectal Cancer
10. The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved Progression Free Survival When Given Before and After Surgery in Patients With Resectable Liver Metastases From Colorectal Cancer
11. Othera Pharmaceuticals Announces Upcoming Presentation Based Upon Expanded Understanding of Lead Compound Mechanism of Action
Post Your Comments:
(Date:3/30/2015)... , March 30, 2015 ... My Diabetes Emergency Plan at the 2015 @NatHurricaneCon ... to be prepared to manage your #diabetes before emergencies ... (ACE) – the charitable, educational and scientific arm of ... joined forces with Lilly Diabetes to share the ...
(Date:3/30/2015)... 2015  The investigational S- equol nutritional supplement ... symptoms, such as hot flashes, according to a new ... Health .[i] "Current data suggest that women ... vasomotor symptoms and possibly additional benefits, such as skin ... equol, physicians and health care professionals may consider the ...
(Date:3/30/2015)... WHITE PLAINS, N.Y. , March 30, 2015 /PRNewswire-USNewswire/ ... developing new treatments for patients with a rare and ... from a recent licensing agreement with a new biotechnology ... has been funding this work, led by Assistant Professor ... Tomasz Cierpicki , Ph.D., at the University of Michigan, ...
Breaking Medicine Technology:Preparation Is Personal for Those with Chronic Illnesses 2Preparation Is Personal for Those with Chronic Illnesses 3Preparation Is Personal for Those with Chronic Illnesses 4New Scientific Review Suggests Some Women May Benefit from Considering Use of S-equol to Ease Menopause Symptoms 2New Scientific Review Suggests Some Women May Benefit from Considering Use of S-equol to Ease Menopause Symptoms 3New Scientific Review Suggests Some Women May Benefit from Considering Use of S-equol to Ease Menopause Symptoms 4New Scientific Review Suggests Some Women May Benefit from Considering Use of S-equol to Ease Menopause Symptoms 5New Scientific Review Suggests Some Women May Benefit from Considering Use of S-equol to Ease Menopause Symptoms 6Leukemia Research Funded by The Leukemia & Lymphoma Society Gets Infusion of Support from Startup Biotechnology Company 2Leukemia Research Funded by The Leukemia & Lymphoma Society Gets Infusion of Support from Startup Biotechnology Company 3
... -- ImClone,Systems Incorporated and Bristol-Myers Squibb Company ... ERBITUX(R) (Cetuximab) plus,gemcitabine (a chemotherapy) in patients ... did not meet its,primary endpoint of improving ... Oncology Group (SWOG), a cancer,center network sponsored ...
... ALTO, Calif., April 09, 2007 /PRNewswire-FirstCall/ --,Telik, ... its,multicenter Phase 2 trial of the triplet ... paclitaxel will be,presented at the 98th annual ... (AACR) in Los Angeles. Preclinical studies of,cellular ...
Cached Medicine Technology:Data Available from Erbitux Phase III Study in First-Line Treatment,of Advanced Pancreatic Cancer 2Data Available from Erbitux Phase III Study in First-Line Treatment,of Advanced Pancreatic Cancer 3Data Available from Erbitux Phase III Study in First-Line Treatment,of Advanced Pancreatic Cancer 4Data Available from Erbitux Phase III Study in First-Line Treatment,of Advanced Pancreatic Cancer 5Data Available from Erbitux Phase III Study in First-Line Treatment,of Advanced Pancreatic Cancer 6Data Available from Erbitux Phase III Study in First-Line Treatment,of Advanced Pancreatic Cancer 7Data Available from Erbitux Phase III Study in First-Line Treatment,of Advanced Pancreatic Cancer 8Data Available from Erbitux Phase III Study in First-Line Treatment,of Advanced Pancreatic Cancer 9Telik Announces Telcyta Clinical and Preclinical Presentations at,AACR Meeting 2Telik Announces Telcyta Clinical and Preclinical Presentations at,AACR Meeting 3
(Date:3/31/2015)... March 31, 2015 The report ... (Reagents, Standards), Test Type (APTT, Prothrombin Time/INR, D-Dimer, ... Hospital)–Forecast to 2019” analyzes and studies the major ... America, Europe, Asia-Pacific and the Rest of the ... market is expected to reach $3.58 billion by ...
(Date:3/31/2015)... California (PRWEB) March 31, 2015 ... company that specializes in providing online solutions ... announced today it has achieved full accreditation ... Healthcare Network Accreditation Program (HNAP) from the ... , EHNAC’s HNAP accreditation runs in two-year ...
(Date:3/31/2015)... Diane Blackburn-Zambetti is the Director of ... Research Foundation (Meso Foundation). Blackburn-Zambetti will present an ... the BoRit Asbestos Superfund Citizen Advisory Group Meeting ... discuss anatomy, six types of asbestos, asbestos products, ... prevention and proper communication with your healthcare provider. ...
(Date:3/31/2015)... 2015 Dr. Stewart Shofner of ... sunshine; however, it's important to be aware of hazards related ... say more than 90 percent of eye injuries can ... safety glasses. Dr. Shofner shares five popular activities and important ... Yard Work. While using a lawn mower, leaf-blower, weed trimmer, ...
(Date:3/31/2015)... 2015 In a normal year for ... are anxiously awaited. After a winter of waiting, cabin ... winter snowpack in the mountain high country melts back ... the high trails. The winter of 2014-2015, according to ... very different. For the first time ever many high ...
Breaking Medicine News(10 mins):Health News:The Global Coagulation Analyzers Market will be Valued at $3.58 Billion in 2019 - MarketsandMarkets 2Health News:The Global Coagulation Analyzers Market will be Valued at $3.58 Billion in 2019 - MarketsandMarkets 3Health News:The Global Coagulation Analyzers Market will be Valued at $3.58 Billion in 2019 - MarketsandMarkets 4Health News:DentalXChange Achieves EHNAC Healthcare Network Accreditation for Fifth Consecutive Time 2Health News:DentalXChange Achieves EHNAC Healthcare Network Accreditation for Fifth Consecutive Time 3Health News:Mesothelioma Foundation to speak at BoRit Asbestos Superfund Citizen Advisory Group Meeting 2Health News:Popular Springtime Activities That Could Cause Irreversible Eye Damage by Renowned Eye Surgeon Dr. Stewart Shofner 2Health News:Popular Springtime Activities That Could Cause Irreversible Eye Damage by Renowned Eye Surgeon Dr. Stewart Shofner 3Health News:Popular Springtime Activities That Could Cause Irreversible Eye Damage by Renowned Eye Surgeon Dr. Stewart Shofner 4Health News:2014-15 winter drought offers unique opportunity for Oregon and California hikers and backpackers reports fresh water advocate 2Health News:2014-15 winter drought offers unique opportunity for Oregon and California hikers and backpackers reports fresh water advocate 3
... 7 Natural Alternatives International, Inc. ("NAI") (Nasdaq: ... and marketer of customized nutritional supplements, today announced ... Randell Weaver,s employment with NAI ended.NAI also announced ... with Wells Fargo Bank. Among other changes ...
... Legislation Aimed at Protecting Medicare Beneficiaries Introduced on ... 7 Physical therapy ... limited by arbitrary financial caps under legislation introduced ... according to the American Physical Therapy Association (APTA). ...
... Acute lymphoblastic leukemia is most common pediatric cancer , , ... leukemia cells predicts which children with acute lymphoblastic leukemia ... online Jan. 7 in the New England Journal ... physicians fine-tune treatment for different subsets of patients. , ...
... SB 203, known as Emily,s Law, has received ... in the state of Ohio. Named after Emily Jerry, ... pharmacy technicians. The law, which was originally sponsored by ... National Pharmacy Technician Association. Emily,s Story , Emily ...
... used to treat heart failure, slowed cell growth, study ... a drug used for many years to treat irregular ... cancer-fighting agent, researchers report. , Cancer cells need to ... these cells are oxygen-deprived and need to switch on ...
... A medical revolution emerges when,technology blends with smart ... new Smart OR(TM) - a specialized neurosurgical suite ... , (Photo: http://www.newscom.com/cgi-bin/prnh/20081016/CLTH057 ... configuration of advanced imagery and mapping technology, the ...
Cached Medicine News:Health News:Natural Alternatives International, Inc. Announces Change in Executive Officer and Loan Modification and Extension 2Health News:Senate and House Introduce Legislation to Repeal Therapy Caps 2Health News:Senate and House Introduce Legislation to Repeal Therapy Caps 3Health News:Gene Governs Response to Leukemia Chemotherapy 2Health News:Emily's Law for Regulating Pharmacy Technicians Signed by Ohio Governor 2Health News:Emily's Law for Regulating Pharmacy Technicians Signed by Ohio Governor 3Health News:Heart Drug May Be a Cancer Fighter 2Health News:A New, 'Smart' Approach to Brain and Spine Surgery 2Health News:A New, 'Smart' Approach to Brain and Spine Surgery 3
... an in-vitro diagnostic test kit for ... cruzi in human serum/plasma. This test ... using gelatin particles coated with inactivated ... particles are agglutinated in the presence ...
The Cellabs T. cruzi IgG CELISA is a direct ELISA kit designed to detect antibodies produced during T. cruzi infections (Chagas disease)....
Inquire...
Silicone ICD lead...
Medicine Products: